We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc Health (TDOC) Down 8.1% Since Q4 Earnings Release
Read MoreHide Full Article
Teladoc Health, Inc.'s (TDOC - Free Report) shares have declined 8.1% since it reported fourth-quarter 2022 results on Feb 22. The quarterly results suffered from an elevated expense level, partly offset by strong growth in access fees and visits.
TDOC reported fourth-quarter 2022 adjusted loss of 23 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents but wider than our estimate of 15 cents. TDOC had delivered an adjusted loss per share of 7 cents a year ago.
Operating revenues improved 15% year over year to $637.7 million (within the management’s expected range of $625-$640 million). The top line outpaced the consensus mark by a whisker and our estimate of $627.4 million.
Teladoc Health, Inc. Price, Consensus and EPS Surprise
Revenues from Access Fees (which comprised 86.8% of total quarterly revenues) amounted to $553.7 million, which advanced 16% year over year in the quarter under review. The figure matched the consensus mark but surpassed our estimate of $550.7 million.
Visit fee revenues, which were earlier reported separately, are now combined with the other revenue component. TDOC generated $84 million of other revenues, which rose 10% year over year.
On a geographical basis, revenues from the United States grew 15% year over year to $554.4 million and accounted for 86.9% of total revenues. International revenues improved 17% year over year to $83.3 million in the fourth quarter.
Adjusted EBITDA of $94.1 million jumped 22% year over year. The figure was well within management’s view of $88-$98 million and also came above our estimate of $93.5 million.
The adjusted gross margin of Teladoc Health improved 200 basis points (bps) year over year to 70.4% in the quarter under review.
Total expenses of $4,453.3 million increased more than seven-fold year over year due to increased costs of revenues as well as expenses related to advertising and marketing, technology and development, general and administrative and, depreciation and amortization.
Segmental Update
In the fourth quarter of 2022, Teladoc Health unveiled two segments namely Teladoc Health Integrated Care (“Integrated Care”) and BetterHelp. The first segment encompasses a portfolio of global virtual medical services consisting of general medical, expert medical services, specialty medical, chronic condition management and mental health. The unit is also entrusted with extending technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment provides virtual therapy and other wellness services throughout the globe.
In the quarter under review, TDOC reported revenues of $357.1 million in its Integrated Care segment. The figure grew 6% year over year. BetterHelp segment’s revenues of $277 million climbed 29% year over year. Adjusted EBITDA of Integrated Care and BetterHelp amounted to $44 million and $53 million, respectively, denoting increases of 33.3% and 23.3% from their corresponding prior-year quarter’s reported figures.
Visits & Memberships
Total visits came in at 4.8 million (within the expectation of 4.7-4.9 million), which advanced 8% year over year in the fourth quarter.
U.S. Integrated Care Members witnessed an uptick of 7% on a year-over-year basis to 83.3 million as of Dec 31, 2022.
Financial Update (as of Dec 31, 2022)
Teladoc Health exited the fourth quarter with cash and cash equivalents of $918.2 million, which advanced 2.8% from the 2021-end level. Total assets of $4,345.4 million declined more than four-fold from the figure in 2021 end.
Debt amounted to $1,535.3 million, up 25.3% from the figure as of Dec 31, 2021. Total stockholders’ equity declined nearly seven-fold from the 2021-end level to $2,307.7 million.
In the quarter under review, net operating cash flow decreased 21.2% year over year to $65.5 million, Free cash flows were recorded at $11.7 million, which declined more than five-fold year over year.
Guidance
Q1
For first-quarter 2023, Teladoc Health anticipates total revenues to be between $610 million and $625 million. Adjusted EBITDA is estimated within $42-$50 million. Net loss per share is expected within 45-55 cents. U.S. Integrated Care Members are forecasted to stay in the 84-85 million range.
Full Year
For 2023, revenues are estimated to be between $2,550 million and $2,675 million, the mid-point of which indicates an improvement of 8.5% from the 2022 figure of $2,406.8 million.
Adjusted EBITDA is anticipated to be in the range of $275-$325 million, the mid-point of which suggests 21.7% growth from the 2022 figure of $246.5 million.
Net loss per share is predicted within $1.25-$1.75. U.S. Integrated Care Members are expected in the 84-86 million band.
Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of AMN Healthcare Services, Inc. (AMN - Free Report) , Community Health Systems, Inc. (CYH - Free Report) and Insulet Corporation (PODD - Free Report) beat the Zacks Consensus Estimate.
AMN Healthcare delivered adjusted earnings per share (EPS) of $2.48 in the fourth quarter of 2022, which declined 15.9% year over year. However, the figure surpassed the Zacks Consensus Estimate by 14.3%. AMN registered revenues of $1.13 billion in the fourth quarter, down 17.4% year over year. However, the figure surpassed the Zacks Consensus Estimate by 5.8%. In the quarter under review, gross profit fell 13.6% to $375.3 million. However, the gross margin expanded 148 basis points (bps) to 33.3%.
Community Health’s fourth-quarter 2022 adjusted net earnings of $1.50 per share surpassed the Zacks Consensus Estimate of 41 cents per share. Additionally, the bottom line climbed 30.4% year over year. Net operating revenues of CYH slid 2.8% year over year to $3,142 million in the quarter under review. Also, the top line fell shy of the consensus mark of $3,170 million. Admissions grew 1.9% year over year. Patient days tumbled 7.5% year over year.
Insulet reported adjusted earnings of 55 cents per share in fourth-quarter 2022, up 31% from the year-ago period’s earnings of 42 cents. Fourth-quarter 2022 earnings exceeded the Zacks Consensus Estimate for adjusted earnings by 129.2%. PODD’s revenues totaled $369.7 million, beating the Zacks Consensus Estimate by 11.8%. Moreover, the top line jumped 20.1% from the year-ago quarter’s number (up 22.6% at the constant exchange rate or CER). Total Omnipod revenues of $366.4 million reflected an increase of 32.8% year over year (up 35.6% at CER).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Teladoc Health (TDOC) Down 8.1% Since Q4 Earnings Release
Teladoc Health, Inc.'s (TDOC - Free Report) shares have declined 8.1% since it reported fourth-quarter 2022 results on Feb 22. The quarterly results suffered from an elevated expense level, partly offset by strong growth in access fees and visits.
TDOC reported fourth-quarter 2022 adjusted loss of 23 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents but wider than our estimate of 15 cents. TDOC had delivered an adjusted loss per share of 7 cents a year ago.
Operating revenues improved 15% year over year to $637.7 million (within the management’s expected range of $625-$640 million). The top line outpaced the consensus mark by a whisker and our estimate of $627.4 million.
Teladoc Health, Inc. Price, Consensus and EPS Surprise
Teladoc Health, Inc. price-consensus-eps-surprise-chart | Teladoc Health, Inc. Quote
Operational Update
Revenues from Access Fees (which comprised 86.8% of total quarterly revenues) amounted to $553.7 million, which advanced 16% year over year in the quarter under review. The figure matched the consensus mark but surpassed our estimate of $550.7 million.
Visit fee revenues, which were earlier reported separately, are now combined with the other revenue component. TDOC generated $84 million of other revenues, which rose 10% year over year.
On a geographical basis, revenues from the United States grew 15% year over year to $554.4 million and accounted for 86.9% of total revenues. International revenues improved 17% year over year to $83.3 million in the fourth quarter.
Adjusted EBITDA of $94.1 million jumped 22% year over year. The figure was well within management’s view of $88-$98 million and also came above our estimate of $93.5 million.
The adjusted gross margin of Teladoc Health improved 200 basis points (bps) year over year to 70.4% in the quarter under review.
Total expenses of $4,453.3 million increased more than seven-fold year over year due to increased costs of revenues as well as expenses related to advertising and marketing, technology and development, general and administrative and, depreciation and amortization.
Segmental Update
In the fourth quarter of 2022, Teladoc Health unveiled two segments namely Teladoc Health Integrated Care (“Integrated Care”) and BetterHelp. The first segment encompasses a portfolio of global virtual medical services consisting of general medical, expert medical services, specialty medical, chronic condition management and mental health. The unit is also entrusted with extending technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment provides virtual therapy and other wellness services throughout the globe.
In the quarter under review, TDOC reported revenues of $357.1 million in its Integrated Care segment. The figure grew 6% year over year. BetterHelp segment’s revenues of $277 million climbed 29% year over year. Adjusted EBITDA of Integrated Care and BetterHelp amounted to $44 million and $53 million, respectively, denoting increases of 33.3% and 23.3% from their corresponding prior-year quarter’s reported figures.
Visits & Memberships
Total visits came in at 4.8 million (within the expectation of 4.7-4.9 million), which advanced 8% year over year in the fourth quarter.
U.S. Integrated Care Members witnessed an uptick of 7% on a year-over-year basis to 83.3 million as of Dec 31, 2022.
Financial Update (as of Dec 31, 2022)
Teladoc Health exited the fourth quarter with cash and cash equivalents of $918.2 million, which advanced 2.8% from the 2021-end level. Total assets of $4,345.4 million declined more than four-fold from the figure in 2021 end.
Debt amounted to $1,535.3 million, up 25.3% from the figure as of Dec 31, 2021. Total stockholders’ equity declined nearly seven-fold from the 2021-end level to $2,307.7 million.
In the quarter under review, net operating cash flow decreased 21.2% year over year to $65.5 million, Free cash flows were recorded at $11.7 million, which declined more than five-fold year over year.
Guidance
Q1
For first-quarter 2023, Teladoc Health anticipates total revenues to be between $610 million and $625 million. Adjusted EBITDA is estimated within $42-$50 million. Net loss per share is expected within 45-55 cents. U.S. Integrated Care Members are forecasted to stay in the 84-85 million range.
Full Year
For 2023, revenues are estimated to be between $2,550 million and $2,675 million, the mid-point of which indicates an improvement of 8.5% from the 2022 figure of $2,406.8 million.
Adjusted EBITDA is anticipated to be in the range of $275-$325 million, the mid-point of which suggests 21.7% growth from the 2022 figure of $246.5 million.
Net loss per share is predicted within $1.25-$1.75. U.S. Integrated Care Members are expected in the 84-86 million band.
Zacks Rank
Teladoc Health currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of AMN Healthcare Services, Inc. (AMN - Free Report) , Community Health Systems, Inc. (CYH - Free Report) and Insulet Corporation (PODD - Free Report) beat the Zacks Consensus Estimate.
AMN Healthcare delivered adjusted earnings per share (EPS) of $2.48 in the fourth quarter of 2022, which declined 15.9% year over year. However, the figure surpassed the Zacks Consensus Estimate by 14.3%. AMN registered revenues of $1.13 billion in the fourth quarter, down 17.4% year over year. However, the figure surpassed the Zacks Consensus Estimate by 5.8%. In the quarter under review, gross profit fell 13.6% to $375.3 million. However, the gross margin expanded 148 basis points (bps) to 33.3%.
Community Health’s fourth-quarter 2022 adjusted net earnings of $1.50 per share surpassed the Zacks Consensus Estimate of 41 cents per share. Additionally, the bottom line climbed 30.4% year over year. Net operating revenues of CYH slid 2.8% year over year to $3,142 million in the quarter under review. Also, the top line fell shy of the consensus mark of $3,170 million. Admissions grew 1.9% year over year. Patient days tumbled 7.5% year over year.
Insulet reported adjusted earnings of 55 cents per share in fourth-quarter 2022, up 31% from the year-ago period’s earnings of 42 cents. Fourth-quarter 2022 earnings exceeded the Zacks Consensus Estimate for adjusted earnings by 129.2%. PODD’s revenues totaled $369.7 million, beating the Zacks Consensus Estimate by 11.8%. Moreover, the top line jumped 20.1% from the year-ago quarter’s number (up 22.6% at the constant exchange rate or CER). Total Omnipod revenues of $366.4 million reflected an increase of 32.8% year over year (up 35.6% at CER).